SCHEMBL2575339

SCHEMBL2575339

OC(c1cccc(F)c1)c1ccccc1OCc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 1/20 0.60
SLC6A5 Q9Y345 1/20 0.60
LMNA P02545 4/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
LIPE Q05469 1/20 0.43
DRD2 P14416 1/20 0.43
DRD1 P21728 1/20 0.43
MAPK1 P28482 2/20 0.43
MAPT P10636 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MRGPRX4 Q96LA9 2/20 0.42
CNR2 P34972 1/20 0.42
LRRK2 Q5S007 1/20 0.41
SGMS2 Q8NHU3 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31041187 0.86 SLC6A9 (0.47) SLC6A9SLC6A5LMNAL3MBTL1LIPE
SCHEMBL477534 0.85 DRD2 (0.55) SLC6A9SLC6A5LMNAL3MBTL1LIPE
SCHEMBL17064340 0.85 MAOB (0.51) SLC6A9SLC6A5LMNAL3MBTL1LIPE
SCHEMBL17064885 0.83 SLC6A9 (0.47) SLC6A9SLC6A5LMNADRD2DRD1
SCHEMBL2580807 0.83 PPIA (0.47) SLC6A9SLC6A5L3MBTL1MRGPRX4ALDH1A1
SCHEMBL2580244 0.82 MAOB (0.55) LMNAL3MBTL1DRD2MAPK1LRRK2
SCHEMBL23748274 0.80 MAPT (0.49) SLC6A9SLC6A5LMNAL3MBTL1DRD2
SCHEMBL14415719 0.80 SLC6A2 (0.44) LMNAALDH1A1SMN1; SMN2
SCHEMBL2577584 0.80 LMNA (0.48) SLC6A9SLC6A5LMNAMAPK1TDP1
SCHEMBL7372304 0.80 NPC1 (0.48) SLC6A9SLC6A5MRGPRX4ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
CN-101010276-B Cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing same CHUGAI PHARMACEUTICAL CO LTD 2011-01-12 CN disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
CN-101010276-A Novel cyclohexane derivative, prodrug thereof, salt thereof, and therapeutic agent for diabetes containing the same CHUGAI PHARMACEUTICAL CO LTD (JP) 2007-08-01 CN disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 SLC6A9 1651/4885SLC6A5 1123/4885LMNA 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.